pramlintide trade name symlin injectable amylin analogue drug diabetes type developed amylin pharmaceuticals wholly owned subsidiary pramlintide sold acetate salt pramlintide analogue amylin small peptide hormone released bloodstream Î² cells pancreas along insulin like insulin amylin completely absent individuals type synergy endogenous amylin pramlintide aids regulation blood glucose slowing gastric emptying promoting satiety via hypothalamic receptors different receptors inhibiting inappropriate secretion glucagon catabolic hormone opposes effects insulin amylin pramlintide also effects raising acute firstphase insulin response threshold following mealcitation needed reduction glycated hemoglobin weight loss shown insulintreated patients type diabetes taking pramlintide adjunctive research field pramlintide experimented used potential treatment drug pramlintide demonstrated ability decrease amyloid beta plaques alzheimers disease mouse pramlintide approved fda use type type diabetic patients use required pramlintide allows patients use less insulin lowers average blood sugar levels substantially reduces otherwise would large unhealthy rise blood sugar occurs diabetics right eating apart insulin analogs pramlintide drug approved fda lower blood sugar type diabetics since insulin early since native human amylin highly amyloidogenic potentially toxic strategy designing pramlintide substitute residues rat amylin less presumably retains clinical activity proline residues known structurebreakingclarification needed residues directly grafted human sequence despite enhanced stability compared human amylin however pramlintide still able organize amyloid amino acid sequences pramlintide positively charged proteincitation needed httpsenwikipediaorgwikipramlintide